Evonik Faces Pivotal Week with Earnings and Potential US Tariff Recovery

Evonik's 2025 results show a 7% revenue drop to €14.1B but improved net profit. Dividend cut to €1.00/share as firm shifts policy for flexibility amid restructuring.

As Evonik prepares to release its full-year 2025 results this week, a recent U.S. legal ruling has introduced an unexpected variable. The German specialty chemicals group is examining whether it could reclaim certain duties now deemed unlawful. While the financial impact appears limited, investor focus remains squarely on Wednesday's figures, the forward guidance, and the company's revised dividend policy.

Annual Results Preview: Key Figures Already Known

The company will publish its complete financial statement for 2025 on March 4. Preliminary data has already been disclosed, showing adjusted EBITDA of €1.874 billion, aligning with its guidance of approximately €1.9 billion. Annual revenue reached €14.1 billion, a decline of roughly 7% from the prior year.

Evonik reported a net profit of €265 million, an improvement from €222 million in 2024. Market participants will scrutinize the quality of these earnings and the strength of cash flow generation, seeking reassurance about the firm's resilience in a challenging economic climate.

The Dividend and Strategic Restructuring

For the 2025 fiscal year, the dividend is set to decrease to €1.00 per share from €1.17. Starting in 2026, Evonik plans to distribute 40% to 60% of its adjusted net income, a policy shift designed to bolster financial flexibility for investments and further debt reduction.

These measures accompany the ongoing "Evonik Tailor Made" efficiency initiative. The program is expected to yield additional cost savings in 2026, which will involve cutting up to 2,000 positions. Furthermore, SYNEQT, the operating company for the Marl and Wesseling chemical sites, was spun off as an independent entity at the start of the year.

Management maintains a cautious outlook. For 2026, Evonik anticipates adjusted EBITDA in a range of €1.7 to €2.0 billion. CEO Christian Kullmann has indicated he does not foresee a rapid recovery for the sector in the near term. The group continues to target a mid-term return on capital employed (ROCE) of 11%.

US Tariff Ruling: A Limited Financial Opportunity

A February 20th decision by the U.S. Supreme Court, which invalidated a portion of tariffs levied under an older statute, has prompted Evonik to assess potential refunds. Interim CFO Claus Rettig confirmed on February 26 that the company is actively evaluating its options, with a potential sum in the "lower double-digit millions" of euros.

However, Evonik will not take concrete steps until the U.S. government's response to the ruling is clear. The company emphasized that its direct exposure to U.S. trade measures has been manageable, as many products for the American market are manufactured locally, reducing vulnerability to cross-border duties.

Market Sentiment and Upcoming Catalysts

Prevailing market caution is reflected in the share price. The stock closed at €14.73 on Friday, down 1.60%, and has declined 23.14% over the past twelve months. Notably, the Relative Strength Index (RSI) stands at a very low 15.8, signaling deeply oversold conditions—a technical indicator that typically only gains traction when fundamental news flow turns positive.

Following the March 4th earnings release, the next key dates are the Q1 2026 quarterly report on May 8 and the virtual Annual General Meeting on June 3, where the dividend and the new distribution strategy will be put to a shareholder vote.